<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>Ministry of Health &amp; Welfare : ABOUT MOHW &gt; Press Release View Content</title>
<link href="../../css/eng/mwf_eng.css" rel="stylesheet" type="text/css"/>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script src="../../js/common.js" type="text/javascript"></script>
<script src="../../js/mw_eng.js" type="text/javascript"></script>
<script type="text/javascript">

//<![CDATA[



	// ¸®½ºÆ®·Î ÀÌµ¿

	function jsList()

	{

		var form = document.fmList;

		form.action = "ssg0111ls.jsp";

		form.submit();

	}



	//³»¿ë º¸±â

	function goView(seq)

	{

		var form = document.fmView;

		form.CONT_SEQ.value = seq;

		form.action = "ssg0111vw.jsp";

		form.submit();

	}



	//ÇÏ´Ü ¸®½ºÆ® ÆäÀÌÁö ÀÌµ¿

	function goPage( page)

	{

		var form = document.fmList;

		form.page.value = page;

		form.submit();

	}



	//ÆÄÀÏ ´Ù¿î·Îµå.

	function fileDownLoad(fileSeq)

	{

		if( confirm( "Do you wish to download now?") == true ) {

			var form = document.fmView;

			form.FILE_SEQ.value = fileSeq;

			form.action = "/front_new/modules/download.jsp";

			form.submit();

		}

	}

//]]>

</script>
</head>
<body>
<!-- ¹Ù·Î°¡±â ¸µÅ© -->
<p id="skip-navi">
<a href="#contents">go to the contents</a>
<a href="#snb">go to the menu</a>
</p>
<!-- //¹Ù·Î°¡±â ¸µÅ© -->
<!-- header -->
<div id="wrap">
<!-- head -->
<div class="sbHead" id="head">
<!-- header -->
<div id="header">
<!-- ·Î°í -->
<h1 class="logo"><a href="../261f58801c1da21d0b6f7021b30b648b"><img alt="ministry of health and welfare" src="../../images/eng/common/logo.gif"/></a></h1>
<div class="kor_sym">
<a href="../../../moi.go.kr/eng/sub/a03/nationalSymbol/d5a2e22490af7d4414516807b47a6064" target="_blank" title="new browser"><img alt="National Symbols of the Republic of Korea" src="../../images/eng/common/kor_sym_eng.gif"/></a>
</div>
<!-- function -->
<div class="function">
<!-- [Funciton] - ÆùÆ®»çÀÌÁî -->
<div class="unit">
<div class="ft_size">
<button class="plus" onclick="fontSizeWrap.btnPlus();" type="button"><span class="hide">expand</span></button>
<button class="minus" onclick="fontSizeWrap.btnMinus();" type="button"><span class="hide">reduce</span></button>
<span class="Font_Size"><span class="hide">Font Size</span></span>
</div>
<script type="text/javascript">var fontSizeWrap = new fontSize();</script>
<!-- //[Funciton] - ÆùÆ®»çÀÌÁî -->
<!-- ¾ð¾îº° ¸µÅ© -->
<ul class="global_language">
<li class="mobile"><a href="../../m_eng/50b06ecdc2a14f90913d780c3460fca4" target="_blank" title="new browser"><span class="hide">Mobile</span></a></li>
<li class="Korean"><a href="../../front_new/647a6a76a15a5a8bfc6d5f73d0d9d4d1" target="_blank" title="new browser"><span class="hide">Korean</span></a></li>
<li class="sitemap"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><span class="hide">sitemap</span></a></li>
<li class="a-z"><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><span class="hide">A-Z Index</span></a></li>
</ul>
<!-- //¾ð¾îº° ¸µÅ© -->
<!-- ¸Þ´º¼³Á¤ -->
<div class="mnsetup">
<div class="btnsetup"><a class="btnms" href="#msetup_layer" id="svcmore_h"><span class="hide">my menu</span></a></div>
<div class="msetup_layer" id="msetup_layer">
<h2>
<img alt="Menu setup" src="../../images/eng/main/musetup.gif"/>
</h2>
<div class="mnsetup_cont">
<ul class="list" id="fmenu"><li>My menu list</li></ul>
</div>
<div class="cg_contwrap">
<div class="cg_cont">
<!-- ÀüÃ¼¸ñ·Ï -->
<ul class="ms_category">
<li>
<input class="input-check" id="mw_100103" name="setmenu" type="checkbox" value="/eng/sg/ssg0103mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100103|100103|Organization"/>
<label for="mw_100103">Organization</label>
</li>
<li>
<input class="input-check" id="mw_100113" name="setmenu" type="checkbox" value="/eng/sg/ssg0101mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100113|100113|Contact Us"/>
<label for="mw_100113">Contact Us</label>
</li>
<li>
<input class="input-check" id="mw_100105" name="setmenu" type="checkbox" value="/eng/sg/ssg0105mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100105|100105|Minister's Profile"/>
<label for="mw_100105">Minister's Profile</label>
</li>
<li>
<input class="input-check" id="mw_100111" name="setmenu" type="checkbox" value="/eng/sg/ssg0111ls.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100111|100111|Press Release"/>
<label for="mw_100111">Press Release</label>
</li>
<li>
<input class="input-check" id="mw_10031801" name="setmenu" type="checkbox" value="/eng/jc/sjc0101mn.jsp?PAR_MENU_ID=1003&amp;MENU_ID=10031801|10031801|Policies"/>
<label for="mw_10031801">Policies</label>
</li>
<li>
<input class="input-check" id="mw_100408" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100408|100408|RSS"/>
<label for="mw_100408">RSS</label>
</li>
<li>
<input class="input-check" id="mw_100410" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100410|100410|Privacy Guideline"/>
<label for="mw_100410">Privacy Guideline</label>
</li>
<li>
<input class="input-check" id="mw_100404" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100404|100404|Users Guide"/>
<label for="mw_100404">Users Guide</label>
</li>
</ul>
<!-- //ÀüÃ¼¸ñ·Ï -->
</div>
<!-- ¹öÆ° Á¤·Ä -->
<div class="btn_msetup">
<p class="left"><input alt="default" class="input-image" id="mymenu_default" src="/images/eng/btn/btn_base.gif" type="image"/></p>
<span class="cg_msg">User can personalize the website</span>
<p class="center">
<input alt="confirm" class="input-image" id="mymenu_set" src="/images/eng/btn/btn_confirm.gif" type="image"/>
<!--a href="#" id="mymenu_set" ><img src="/images/front/btn/btn_confirm.gif" alt="È®ÀÎ" /></a-->
<input alt="cancel" class="input-image" id="mymenu_cancel" src="/images/eng/btn/btn_cancel.gif" type="image"/>
</p>
<p class="right"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f">sitemap</a></p>
</div>
<!-- //¹öÆ° Á¤·Ä -->
</div>
<p class="btn-more"><button class="msbtn_close" id="msbtn_close" type="button"><span class="hide">close</span></button></p>
</div>
</div>
<!-- //¸Þ´º¼³Á¤ -->
<!-- °Ë»ö -->
<!-- 

					<div class="search">

						<form method="post" name="fmSearch" action="/eng/cs/scs0401ls.jsp" onsubmit="return searchCommon(this)" >

							<input type="hidden" name="PAR_MENU_ID" value="1004" />

							<input type="hidden" name="MENU_ID" value="100406" />

							<input type="hidden" name="SEARCHKEY" value="TITLE" />				

							<fieldset>

								<legend>search</legend>

								<label for="SEARCHVALUE" class="hide">search value</label>

								<input type="text" id="SEARCHVALUE" name="SEARCHVALUE" class="input-text" />

								<input type="image" class="input-image" src="/images/eng/common/tl_btnsearch.gif" alt="search" />

							</fieldset>

						</form>

					</div>

					 -->
<!-- //°Ë»ö -->
</div><!-- //unit -->
</div>
<!-- //function -->
</div>
<!-- //header -->
</div>
<!-- //head -->
<hr/>
<!-- spot main -->
<div id="spot-sub">
<img alt="A life-long friend who stands by the public" src="../../images/front_eng/sg/img_head_sg.jpg"/>
</div>
<!-- //spot main -->
<hr/>
<!-- container -->
<div class="clear" id="container">
<div id="subwrap">
<!-- snb -->
<div id="snb">
<h2><a href="616feca8de871f8a1f1e040342b5d550"><img alt="About MW" src="../../images/front_eng/title/h2_am.gif"/></a></h2>
<ul id="snbMenu1">
<li><a href="616feca8de871f8a1f1e040342b5d550"><img alt="Vision &amp; Mission" src="../../images/front_eng/title/left_am01.gif"/></a>
</li>
<li><a href="93dae7d73a99735630654fc2fb46a9eb"><img alt="Organization" src="../../images/front_eng/title/left_am02.gif"/></a>
</li>
<li><a href="482124899dc6a43227599ea28a921fea"><img alt="Contact Us" src="../../images/front_eng/title/left_am03.gif"/></a>
</li>
<li><a href="2d75b746f82cbae41316bd3da4ceb30d"><img alt="Minister¡¯s Profile" src="../../images/front_eng/title/left_am04.gif"/></a>
</li>
<li><a href="a2fde158a68020769e116fe2815d95aa"><img alt="Vice Minister¡¯s Profile" src="../../images/front_eng/title/left_am05.gif"/></a>
</li>
<li><a href="8c6914a853d28a0cf2ce417c6d5fe3ce"><img alt="Past Ministers &amp; Vice Ministers" src="../../images/front_eng/title/left_am06.gif"/></a>
</li>
<li><a href="a79fdae6ffae612a0b5f784645afb1db"><img alt="Location" src="../../images/front_eng/title/left_am07.gif"/></a>
</li>
<li class="on"><a href="76b19fd6a92fcb216e55a4e9dea9a4c8"><img alt="Press Release" src="../../images/front_eng/title/left_am08_over.gif"/></a>
</li>
<li><a href="ea8a1ea6f8dcdcb2b03b8ebc89df5ef6"><img alt="129 Call Center" src="../../images/front_eng/title/left_am09.gif"/></a>
</li>
<li><a href="../../../www.epeople.go.kr/jsp/user/on/eng/ebb342dee28c17242d927d0b1019800f" target="_blank"><img alt="Online Petition" src="../../images/front_eng/title/left_am10.gif"/></a>
</li>
</ul>
<h2><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Policies" src="../../images/front_eng/title/h2_pl.gif"/></a></h2>
<ul id="snbMenu2">
<li class="submenu"><img alt="Enhancement of Customized Welfare Services by Life-Cycle Phase" src="../../images/front_new/title/left_pl100321.gif"/>
<ul>
<li><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Reinforcement of support for income growth and work opportunities of low-income people" src="../../images/front_new/title/left_pl10032101.gif"/></a></li>
<li><a href="../jc/6d963af417c35f2c3575a2f47d93315d"><img alt="Welfare services reaching out to people and improvement of public perception" src="../../images/front_new/title/left_pl10032102.gif"/></a></li>
<li><a href="../jc/7c117d987132de318dd869c7e15cd6d1"><img alt="Promotion of rights and interests of children, the disabled, the elderly, etc." src="../../images/front_new/title/left_pl10032103.gif"/></a></li>
<li><a href="../jc/3cd7dc5b01d534d90eba055e35cdf386"><img alt="Reduction of burden of medical expenses, and the reorganization of the system for determining health insurance premiums" src="../../images/front_new/title/left_pl10032104.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Establishment of Health Insurance System centered on People" src="../../images/front_new/title/left_pl100322.gif"/>
<ul>
<li><a href="../jc/6698fa46cb8d35f0f8aeb6f289ab2ce9"><img alt="Reinforcement of patient-oriented medical services" src="../../images/front_new/title/left_pl10032201.gif"/></a></li>
<li><a href="../jc/6194a5e0555dab84754814c541f09b27"><img alt="Strengthening of essential and public health care services and systematic response to infectious diseases" src="../../images/front_new/title/left_pl10032202.gif"/></a></li>
<li><a href="../jc/7603054a50c83c708da6d6702afe3d14"><img alt="Reinforcement of Preventive Health Care" src="../../images/front_new/title/left_pl10032203.gif"/></a></li>
<li><a href="../jc/5975190b9def38149afd3ad48132162f"><img alt="Enhancement of healthcare industry performance and job creation" src="../../images/front_new/title/left_pl10032204.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Strengthening Responses to Demographic Crisis" src="../../images/front_new/title/left_pl100323.gif"/>
<ul>
<li><a href="../jc/8334fe91b7312eb840b99581e90bc297"><img alt="Establishment of a response system for coping with low birthrate" src="../../images/front_new/title/left_pl10032301.gif"/></a></li>
<li><a href="../jc/687f9bcd11741aea5264c8392dc17ffc"><img alt="Improvement of a system for supporting childbirth and parenting" src="../../images/front_new/title/left_pl10032302.gif"/></a></li>
<li><a href="../jc/d59e41ec8156d3ed1193b5f64629cf85"><img alt="Enhancement of preparation for aging society" src="../../images/front_new/title/left_pl10032303.gif"/></a></li>
</ul>
</li>
</ul>
<h2><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Help" src="../../images/front_eng/title/h2_hp.gif"/></a></h2>
<ul id="snbMenu3">
<li><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Users Guide" src="../../images/front_eng/title/left_hp01.gif"/></a>
</li>
<li><a href="../cs/81e6dbd0ed113665170a29b899ab0c21"><img alt="Privacy Guideline" src="../../images/front_eng/title/left_hp04.gif"/></a>
</li>
<li><a href="../cs/bab2f9d80d5980695b6081cb22ceb64b"><img alt="RSS" src="../../images/front_eng/title/left_hp03.gif"/></a>
</li>
<li><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><img alt="Sitemap" src="../../images/front_eng/title/left_hp05.gif"/></a>
</li>
<li><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><img alt="A-Z Index" src="../../images/front_eng/title/left_hp06.gif"/></a>
</li>
</ul>
</div>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script type="text/javascript">
			$('.submenu').last().find('ul').attr('class', 'noline');
			imgMenuOver("snb");
			
			$(function(){
				$(".on").parents('ul').slideDown();
			});	
			
			$(".submenu").click(function(){
				$(".submenu").not($(this)).children('ul').slideUp();
				$(this).children('ul').slideToggle();
			});
		</script>
<!-- //snb -->
<!-- contents -->
<div id="contents">
<!-- mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<div class="mnvisual">
<!-- h2 - Å¸ÀÌÆ² -->
<!-- //h2 - Å¸ÀÌÆ² -->
<!-- location - ÁÖ¼Ò -->
<div id="location"> <a class="home" href="../261f58801c1da21d0b6f7021b30b648b">HOME</a> &gt; <a href="616feca8de871f8a1f1e040342b5d550">ABOUT MOHW</a> &gt; <span class="here">Press Release</span></div>
<!-- //location - ÁÖ¼Ò -->
</div>
<!-- //mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<!-- content-area -->
<div class="content-area">
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
<!-- board -->
<form action="ssg0111vw.jsp" method="post" name="fmView">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="15"/>
<input name="CONT_SEQ" type="hidden" value="292409"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="FILE_SEQ" type="hidden" value=""/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<!-- table:view -->
<table class="view" summary="ABOUT MOHW &gt; Press Release detail.">
<caption>ABOUT MOHW &gt; Press Release</caption>
<colgroup>
<col width="12%"/><col width="38%"/><col width="12%"/><col width="38%"/>
</colgroup>
<tbody>
<tr>
<th scope="row">Subject</th>
<td colspan="3">Daewoong Pharmaceutical Co., Ltd. joins in on successful cases of global advancement by signing an export contract worth 300 billion won</td>
</tr>
<tr>
<th scope="row">Date</th>
<td>2013-10-18</td>
<th scope="row">Hit</th>
<td>4289</td>
</tr>
<tr>
<th scope="row">Contents</th>
<td class="view" colspan="3"><p class="MsoNormal" style="margin: 0cm 0cm 10pt">
<b style="mso-bidi-font-weight: normal"><u><span lang="EN-US" style="font-size: 12pt; line-height: 115%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin"><font color="#000000"><font face="¸¼Àº °íµñ">Daewoong Pharmaceutical Co., Ltd. joins in on successful cases of global advancement by signing an export contract worth 300 billion won<o:p></o:p></font></font></span></u></b></p>
<p align="center" class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%; text-align: center">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p align="center" class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%; text-align: center">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">- The pharmaceutical company secured chances to advance into the U.S. and European markets by signing a contract worth 300 billion won including the technology fees involved in dealing with Botulinum toxin type A in high degrees of purity – <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Nabota (tentative name), a medicine developed and produced in Korea, will advance into advanced pharmaceutical markets in the U.S. and Europe.<o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* (scale of pharmaceutical markets) entire world 1,083 trillion, North America 398 trillion, Europe 293 trillion (resource: IMS Health Data 2012). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The Ministry of Health and Welfare said on September 30<sup>th</sup> that Korean drug maker Daewoong Pharmaceutical Co., Ltd. finalized a 300-million-won contract with Evolus,* a U.S. biotech venture company, to export Nabota which includes the royalty fees. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* Clinical tests and regulatory approval in the U.S. and Europe (Evolus will pay the fees for approval procedures), and will be in charge of supplying and distributing while Daewoong Pharmaceutical produces and exports the medicine. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">This case is in line with this year’s advancements* of Korean companies, and is being interpreted as an indication that Korean companies’ are truly beginning to advance into global markets. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* Beginning with Celltrion which acquired approval for their product from the European Medicines Agency (EMA) (June, 2013), JW Pharmaceutical signed an export contract for a Triple-Chamber Bag for Nutrition with Baxter (July, 2013); Boryung Pharmaceutical Company signed an export contract for the Kanarb Tab. with Central and South American countries (July, 2013); Hanmi Pharm. Co., Ltd. acquired marketing authorization for Esomezol from the U.S. Food and Drug Administration (FDA) (August, 2013); and BC World Pharm Co., Ltd. signed a contract with Japan's Koa Shoji Co., Ltd to export microsphere injections (September, 2013). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Natoba (tentative name), developed by Daewoong, is a Botulinum toxin type A injection that is not only used to treat migraines and muscle paralysis, but can also be used for cosmetic enhancement purposes. After recently passing clinical tests, Natoba is ready to hit the shelves in Korea by the end of this year, and is scheduled to undergo approval procedures for its advancement into the U.S. and European markets through the previously mentioned contract. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* 12 billion won over a span of five years was invested in developing Nabota <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Nabota is being assessed to have the potential to take on the U.S. and European markets, for the reasons that its strain was discovered through a unique Korean patented technology making it currently producible in Korea, that it is a product of high levels of purity compared to previous products which is in turn producing a high quality product, that it has low incidence rates of side effects, and that its price is competitive. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="color: red; line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The scale of U.S. and European markets for this product was 2 trillion won in 2011, and by 2017, when Nabota is expected to enter these markets, the predicted scale is estimated to reach 3.5 trillion won (11% growth in demand every year). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* The scale of the entire market in Korea is 70 billion won (as of 2012) and Meditoxin Injections by Medytox and Botox Injections by Allergan were ranked the top two products in sales, with total combined sales being roughly 17 billion won for the two companies. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Daewoong is an innovative pharmaceutical company and had been supported by the Ministry of Health and Welfare for an R&amp;D project on international joint research to study innovative pharmaceutical companies. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* 250 million won was subsidized to secure advanced standards and research quality on the regulatory approval of foreign countries in order to help advance Botolinum toxin injections (Nabota) into foreign markets. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Daewoong, the only pharmaceutical company in Korea ranking in the World Class 300 Companies, took over the Chinese pharmaceutical company Liaoning Baifeng and acquired the U.S. FDA Abbreviated New Drug Application (ANDA) (May, 2013) approval for Meropenem Injections. For their distinguished achievements, the company received an award for being an innovative pharmaceutical company from the Ministry of Health and Welfare on September 13<sup>th</sup> this year. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; text-indent: 9.75pt; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">* (World Class 300) A system that selects small- and medium-sized companies which have the will and potential to grow into a global company to provide them with a support package. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">A ministry official said that the export contract of Nabota is meaningful for local pharmaceutical companies in that the product act has a good model for success in advancing into major pharmaceutical markets, such as the U.S. and Europe. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">He added that the government will unsparingly support local Korean companies to help their advancement into global markets. Therefore challenging and adventurous investments in R&amp;D, consistent innovation, and active strategic practices will be required for such successful global advancement to occur. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The official also stated that the idea ”we can do it” is spreading throughout the Korean pharmaceutical industry, and this year will be the first year for the industry to begin its journey to become a pharmaceutical powerhouse by the year 2020. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">An antibiotic against super bacteria developed by Dong-A Pharmaceutical, and Zemiglo, the Korean-developed diabetes treatment from LG Life Sciences, are in the process of waiting for approval from the U.S. FDA (end of 2013 ~ first half of 2014).<o:p></o:p></font></font></font></span></p></td>
</tr>
<tr>
<th scope="row">File</th>
<td colspan="3">
<p><img alt="" src="../../images/common/file/icon_file.gif"/> <a href="../../../download.mohw.go.kr/front_new/modules/697c2b1806759b14de9d6f06d6e65545">[ENG][9.30]Daewoong_Pharmaceutical_Co.,_Ltd._joins_in_on_successful_cases_of_global_advancement_by_signing_an_export_contract_worth_300_billion_won.docx (26 KB / Download : 1595)</a></p>
</td>
</tr>
</tbody>
</table>
<!-- /table:view -->
<!-- ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
<div class="btn btm">
<!--  ¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
<a href="69279edea38f89c531ee92dcc558f429"><img alt="list" class="right" src="../../images/eng/common/btn_list.gif"/></a>
<!--  /¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
</div>
<!-- /ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
</form>
<br/>
<br/>
<div class="view_list">
<form action="ssg0111ls.jsp" method="post" name="fmList">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="15"/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<input name="CONT_SEQ" type="hidden" value=""/>
<!-- table head above list -->
<div id="tablehead">
<p>Total <strong>345</strong> Articles</p>
</div>
<!-- /table head above list -->
<table class="list" summary="Publication list.">
<caption>Publication</caption>
<colgroup>
<col width="8%"/><col width="60%"/>
<col width="16%"/><col width="8%"/><col width="8%"/>
</colgroup>
<thead>
<tr>
<th class="first" scope="col">No</th>
<th scope="col">Subject</th>
<th scope="col">Date</th>
<th scope="col">File</th>
<th scope="col">Hit</th>
</tr>
</thead>
<tbody>
<tr>
<td>205</td>
<td class="left"><a href="d212da4cc364d67ddc07b8e71f241a54">Press Release Summary (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1911</td>
</tr>
<tr>
<td>204</td>
<td class="left"><a href="64d92272b5170388c66a1280ec815bda">The Ministry Designates MERS Hospital</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1489</td>
</tr>
<tr>
<td>203</td>
<td class="left"><a href="e089b8c7127913c10030c390e03b02c3">Hospitals with Known MERS Exposure (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1855</td>
</tr>
<tr>
<td>202</td>
<td class="left"><a href="f3782c5996c86af00382db58cd0fca8f">MERS Statistics (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1821</td>
</tr>
<tr>
<td>201</td>
<td class="left"><a href="d03895e98485f90135248f1fb71507df">National Safe Hospital_Entire List</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2423</td>
</tr>
<tr>
<td>200</td>
<td class="left"><a href="dfe801aa78ada3707e6a4e675ca2bb6c">Press Release Summary (June 19)</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2220</td>
</tr>
<tr>
<td>199</td>
<td class="left"><a href="018002895987aec98261a097ed4dde79">Hospitals with Known MERS Exposure</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1640</td>
</tr>
<tr>
<td>198</td>
<td class="left"><a href="09f72e386c73fd723c20199fe6d07228">MERS Statistics (June 19)</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2356</td>
</tr>
<tr>
<td>197</td>
<td class="left"><a href="ea1a8f9ca266ce7697a42aa208fa08bd">Press Release Summary (June 18)</a></td>
<td>2015-06-18</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1752</td>
</tr>
<tr>
<td>196</td>
<td class="left"><a href="a263cea461913e8b28b0a3d5d75c0b54">MERS Statistics (June 18)</a></td>
<td>2015-06-18</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1659</td>
</tr>
</tbody>
</table>
<!-- /table:list -->
<!-- paging -->
<!-- paging -->
<div id="paging">
<a class="btn" href="ebfb6bc3f850eb20122e1021c6e4c0d1"><img alt="first page" src="../../images/eng/common/btn_firstpage.gif"/></a>
<a class="btn" href="ffdc4366d327476f2a2bdd61bea75d3f"><img alt="pre page" src="../../images/eng/common/btn_prepage.gif"/></a>
<a href="b5ac7ead72941feddd2152cd97408423" title="11page">11</a> 

				<a href="43305223367df6986d635c77763975b3" title="12page">12</a> 

				<a href="2711dbddb6de0a13625580768c3557fa" title="13page">13</a> 

				<a href="291c7b2c06ad0f481977e50fbd85795e" title="14page">14</a> 

				<span title="present">15</span> 

				<a href="3d5e6982b8cfbd3ae4834a4e77e21144" title="16page">16</a> 

				<a href="32fde42f13158f6b4f430ac227830ad3" title="17page">17</a> 

				<a href="e9a17658ff68b1011b3bf38b014eea17" title="18page">18</a> 

				<a href="3fbff7a5c45a170ce3270ba839fff4fb" title="19page">19</a> 

				<a href="095823f82b64fc9c0ab92d552e48e0b3" title="20page">20</a> 

				<a class="btn" href="6c8765ade6af448afd7277d09046c33a"><img alt="next page" src="../../images/eng/common/btn_nextpage.gif"/></a>
<a class="btn" href="2d7e34ab1d5e2a71b1530de73fd24299"><img alt="last page" src="../../images/eng/common/btn_lastpage.gif"/></a>
</div>
<!-- /paging -->
<!-- /paging -->
</form>
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
</div>
</div>
<!-- /contents -->
</div>
</div>
<!-- footer -->
<!-- footer -->
<div id="footer">
<div class="foot">
<p class="flogo"><img alt="ministry of health and welfare" src="../../images/eng/common/flogo.gif"/></p>
<div class="finfo">
<address><img alt="13, Doum 4-ro, Sejong, (30113) Korea ¤ÓCALL CENTER 82-129" src="../../images/eng/common/foot_address.gif"/></address>
<p class="copyright"><img alt="Copyright(C) By MOHW. All rights reserved." src="../../images/eng/common/foot_copyright.gif"/></p>
</div>
<!-- ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
<p class="visits">Daily visits : <strong>198</strong></p>
<!--// ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
</div>
</div>
<!-- //footer -->
</div>
<div id="returntotop"><a href="#skip-navi">go to the top</a></div>
<script type="text/javascript">
//<![CDATA[
function jsOpenSite(formEl) {	
	var errorMessage = null;
	var objFocus = null;
	if (formEl.sitelink.value.length == 0) {
		errorMessage = "please! select a site to move!";
		objFocus = formEl.sitelink;
	} 
	if(errorMessage != null) {
		alert(errorMessage);
		objFocus.focus();
		return false;
	}
	return true;
}
//]]>	
</script>
<script type="text/javascript">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-101800795-1', 'auto');
  ga('send', 'pageview');

</script>
<!-- /footer -->
</div>
</body>
</html>